The £17m Biotechnology Building has processed its first commercial-scale batch of antigen, which will be used in a number of new aquaculture vaccines in Benchmark's product pipeline.
Work on the final validation of the facility to ensure compliance with EU Good Manufacturing Practices (GMP) is underway and once fully licensed the increased capacity will allow the Company to significantly expand the number and range of vaccines it produces.
The 2,500-square-metre facility is set to be one of the most capable EU GMP antigen production facilities in Europe.
Malcolm Pye, Benchmark CEO, commented;
“This is a significant milestone for Benchmark. The new facility provides the foundation for the large-scale antigen manufacture and testing of our new pipeline products, and represents the engine room through which our ground-breaking products can be delivered on a large commercial scale.”